COLL Collegium Pharmaceutical (COLL) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001267565
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
164
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $430.4K priced
What the filings say about COLL
Insiders, 180 days
-$628.6K net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$603.3K
1 notice
Collegium Pharmaceutical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, COLLEGIUM PHARMACEUTICAL, INC insiders sold a net $628.6K of stock across 100 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on May 15, 2026.
- The trade is 0.0% of the 83,952 shares held after it.
- 2 other insiders sold within 30 days.
- 164 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Freund John Gordon sold about $681 of COLL on May 18, 2026; 2 other insiders sold within 30 days and 164 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 8, 2025.
- The trade is 4.9% of the 83,972 shares held after it.
- 2 other insiders sold within 30 days.
- 164 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Freund John Gordon sold about $142.5K of COLL on May 15, 2026; 2 other insiders sold within 30 days and 164 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 25.0% of the 18,017 shares held after it.
- 2 other insiders sold within 30 days.
- 164 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lurker Nancy sold about $161.9K of COLL on May 13, 2026; 2 other insiders sold within 30 days and 164 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 14, 2024.
- The trade is 14.0% of the 62,259 shares held after it.
- 2 other insiders sold within 30 days.
- 164 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BOHLIN GAREN G sold about $323.5K of COLL on May 11, 2026; 2 other insiders sold within 30 days and 164 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 9, 2026.
- The trade is 18.1% of the 77,071 shares held after it.
- 1 other insider sold within 30 days.
- 164 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & General Counsel Dieter David sold about $488.0K of COLL on Mar 18, 2026; 1 other insider sold within 30 days and 164 funds added in the latest 13F quarter.100 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$628.6K over 180 days
below 57% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
164 funds bought in last quarter
more than 85% of Pharma & Biotech
Revenue
+23.6% year over year
more than 69% of Pharma & Biotech
Margin
8.1% net margin
more than 79% of Pharma & Biotech
Buybacks
$25.1M repurchased, FY to 2025-12-31
below 56% of Pharma & Biotech
Short interest
18.5% of the float short (float per yahoo 2026-10-26) · 6.1 days to cover · settled 2026-09-30
more than 89% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 4 in the prior 90
Why it matters
The absence is the signal: 4 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Sep 30Former Officer Dreyer Scott filed to sell $603.3K by Sep 30 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch COLL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-34.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns COLL: institutional holders (13F)
13F holdings, latest reported quarter
5,441,202 sh
$197.0M
2,147,072 sh
$77.7M
1,882,499 sh
$68.1M
1,632,781 sh
$59.1M
1,632,360 sh
$59.1M
Congress trades in COLL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
COLL planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Dreyer Scott
Filed 2026-09-30
$603.3K
Fallon John A.
Filed 2026-07-17
$497.4K
Fallon John A.
Filed 2026-07-15
$294.0K
COLL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Third Avenue Small-Cap Value Fund
$7.2M position · as of 2026-07-31
3.3%
Invesco Pharmaceuticals ETF
$12.9M position · as of 2026-07-31
2.7%
Invesco Biotechnology & Genome ETF
$7.3M position · as of 2026-07-31
2.6%
CANTOR FITZGERALD EQUITY OPPORTUNITY FUND
$1.9M position · as of 2026-06-30
2.3%
Miller Convertible Total Return ETF
$273.7K position · as of 2026-07-31
2.0%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$6.8M position · as of 2026-06-30
1.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Karnani
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.7M
$7.9M
$3.1M
+125%
+58%
2023
$9.1M
$15.0M
$2.6M
+50%
+19%
2022
$6.9M
$10.5M
$1.8M
+13%
+14%
2021
$7.3M
$5.1M
$2.2M
-9%
+26%
2020
$6.0M
$5.2M
$2.2M
-3%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $628.6K sold by insiders over 180 days, 164 funds added last quarter, $603.3K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
COLL financials
Revenue growth
+23.6%
XBRL, annual
Net margin
8.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$808.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM COLL
| FY Dec 2025 | $780.6M |
| FY Dec 2024 | $631.4M |
| FY Dec 2023 | $566.8M |
| FY Dec 2022 | $463.9M |
| FY Dec 2021 | $276.9M |
| Jun 2026 | $199.9M |
| Mar 2026 | $193.5M |
| Dec 2025 | $205.4M |
| Sep 2025 | $209.4M |
| Jun 2025 | $188.0M |
| Mar 2025 | $177.8M |
| Dec 2024 | $181.9M |
| Sep 2024 | $159.3M |
At each fiscal year end
Single quarter
Net margin, TTM
+5.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM COLL
| FY Dec 2025 | +8.1% |
| FY Dec 2024 | +11.0% |
| FY Dec 2023 | +8.5% |
| FY Dec 2022 | -5.4% |
| FY Dec 2021 | n/a |
| Jun 2026 | -7.5% |
| Mar 2026 | +7.5% |
| Dec 2025 | +8.3% |
| Sep 2025 | +15.0% |
| Jun 2025 | +6.4% |
| Mar 2025 | +1.4% |
| Dec 2024 | +6.9% |
| Sep 2024 | +5.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$328.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM COLL
| FY Dec 2025 | $327.6M |
| FY Dec 2024 | $203.3M |
| FY Dec 2023 | $274.3M |
| FY Dec 2022 | $122.6M |
| FY Dec 2021 | $101.6M |
| Jun 2026 | $70.8M |
| Mar 2026 | $56.8M |
| Dec 2025 | $122.4M |
| Sep 2025 | $78.2M |
| Jun 2025 | $72.4M |
| Mar 2025 | $54.6M |
| Dec 2024 | $84.1M |
| Sep 2024 | -$9.2M |
At each fiscal year end
Single quarter
Debt to equity
0.04x
long-term debt only, 2019-12-31 (79 months older than the period end); equity 2026-06-30
Debt to equity COLL
| FY Dec 2025 | 0.04x |
| FY Dec 2024 | 0.05x |
| FY Dec 2023 | 0.06x |
| FY Dec 2022 | 0.06x |
| FY Dec 2021 | 0.06x |
| Jun 2026 | 0.04x |
| Mar 2026 | 0.04x |
| Dec 2025 | 0.04x |
| Sep 2025 | 0.04x |
| Jun 2025 | 0.05x |
| Mar 2025 | 0.05x |
| Dec 2024 | 0.05x |
| Sep 2024 | 0.05x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
28.69x
TTM operating cash flow over long-term debt only, 2019-12-31 (79 months older than the period end)
Cash flow to debt COLL
| FY Dec 2025 | 28.64x |
| FY Dec 2024 | 17.82x |
| FY Dec 2023 | 23.89x |
| FY Dec 2022 | 10.80x |
| FY Dec 2021 | 9.00x |
| Jun 2026 | 28.69x |
| Mar 2026 | 28.79x |
| Dec 2025 | 28.64x |
| Sep 2025 | 25.30x |
| Jun 2025 | 17.69x |
| Mar 2025 | 17.26x |
| Dec 2024 | 17.82x |
| Sep 2024 | 16.84x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+17.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity COLL
| FY Dec 2025 | +23.7% |
| FY Dec 2024 | +32.6% |
| FY Dec 2023 | +24.7% |
| FY Dec 2022 | -12.6% |
| FY Dec 2021 | n/a |
| Jun 2026 | +17.6% |
| Mar 2026 | +27.4% |
| Dec 2025 | +23.7% |
| Sep 2025 | +23.0% |
| Jun 2025 | +16.2% |
| Mar 2025 | +19.2% |
| Dec 2024 | +32.6% |
| Sep 2024 | +42.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+2.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets COLL
| FY Dec 2025 | +3.8% |
| FY Dec 2024 | +4.9% |
| FY Dec 2023 | +4.2% |
| FY Dec 2022 | -2.7% |
| FY Dec 2021 | n/a |
| Jun 2026 | +2.6% |
| Mar 2026 | +4.6% |
| Dec 2025 | +3.8% |
| Sep 2025 | +3.6% |
| Jun 2025 | +2.7% |
| Mar 2025 | +3.2% |
| Dec 2024 | +4.9% |
| Sep 2024 | +6.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+60.6%
operating income after a 38.3% effective tax rate, over long-term debt only, 2019-12-31 (79 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital COLL
| FY Dec 2025 | +96.9% |
| FY Dec 2024 | +173.1% |
| FY Dec 2023 | +33,280% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +60.6% |
| Mar 2026 | +127.6% |
| Dec 2025 | +96.9% |
| Sep 2025 | +66.2% |
| Jun 2025 | +97.8% |
| Mar 2025 | +123.9% |
| Dec 2024 | +173.1% |
| Sep 2024 | +193.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+11.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed COLL
| FY Dec 2025 | +15.2% |
| FY Dec 2024 | +18.5% |
| FY Dec 2023 | +23.4% |
| FY Dec 2022 | +5.8% |
| FY Dec 2021 | +4.3% |
| Jun 2026 | +11.8% |
| Mar 2026 | +16.0% |
| Dec 2025 | +15.2% |
| Sep 2025 | +13.5% |
| Jun 2025 | +15.1% |
| Mar 2025 | +15.7% |
| Dec 2024 | +18.5% |
| Sep 2024 | +20.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
18.72x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing COLL
| FY Dec 2025 | 27.08x |
| FY Dec 2024 | 15.40x |
| FY Dec 2023 | 26.08x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 11.05x |
| Jun 2026 | 29.19x |
| Mar 2026 | 16.21x |
| Dec 2025 | 27.08x |
| Sep 2025 | 21.73x |
| Jun 2025 | 28.43x |
| Mar 2025 | 24.47x |
| Dec 2024 | 15.40x |
| Sep 2024 | 16.66x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$637.6M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2019-12-31 (79 months older than the period end), minus cash 2026-06-30
Enterprise value COLL
| FY Dec 2025 | $1.2B |
| FY Dec 2024 | $864.9M |
| FY Dec 2023 | $776.3M |
| FY Dec 2022 | $616.7M |
| FY Dec 2021 | $470.8M |
| Jun 2026 | $1.1B |
| Mar 2026 | $792.9M |
| Dec 2025 | $1.2B |
| Sep 2025 | $963.7M |
| Jun 2025 | $844.6M |
| Mar 2025 | $855.2M |
| Dec 2024 | $864.9M |
| Sep 2024 | $1.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+43.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield COLL
| FY Dec 2025 | +22.4% |
| FY Dec 2024 | +22.0% |
| FY Dec 2023 | +27.3% |
| FY Dec 2022 | +15.7% |
| FY Dec 2021 | +15.7% |
| Jun 2026 | +28.0% |
| Mar 2026 | +31.4% |
| Dec 2025 | +22.4% |
| Sep 2025 | +26.2% |
| Jun 2025 | +21.2% |
| Mar 2025 | +20.9% |
| Dec 2024 | +22.0% |
| Sep 2024 | +15.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.97x
P/E over trailing EPS growth of 19%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing COLL
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.27x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.09x |
| Jun 2026 | 1.52x |
| Mar 2026 | 0.24x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 0.27x |
| Sep 2024 | 0.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $780.6M | $631.4M | $566.8M | $463.9M |
| Gross profit | $463.3M | $377.3M | $326.2M | $209.5M |
| Operating income | $179.6M | $169.9M | $167.0M | $33.3M |
| Net income | $63.0M | $69.0M | $48.0M | -$25.0M |
| EPS (diluted) | 1.73 | 1.86 | 1.29 | -0.74 |
| Operating cash flow | $329.3M | $205.0M | $274.7M | $124.2M |
| Cash | $231.3M | $70.6M | $238.9M | $173.7M |
| Buybacks | $25.1M | $60.0M | $75.0M | $14.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
COLL Stock Sonar score 6/7 axes
Find similar shapesCompareCOLL ranks highest on profitability (88th percentile) and financial health (82nd), and lowest on insider conviction (20th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
COLL filings, in plain words
Are Collegium Pharmaceutical insiders buying or selling COLL?
In the 180 days to 2026-10-28, Collegium Pharmaceutical insiders were net sellers, a net $628.6K across purchases and sales reported on Form 4, by 3 sellers.
Are there planned insider sales of COLL?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $603.3K of stock; the latest, by Dreyer Scott, was filed 2026-09-30.
Read the full summary
In the 180 days to 2026-10-28, Collegium Pharmaceutical insiders were net sellers of COLL, a net $628.6K across purchases and sales reported on Form 4 by 3 sellers. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $603.3K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
